Literature DB >> 15069551

Expression of splicing factors in human ovarian cancer.

D-C Fischer1, Kathleen Noack, Ingo B Runnebaum, Dirk O Watermann, Dirk G Kieback, Stefan Stamm, Elmar Stickeler.   

Abstract

Alternative splicing represents an important nuclear mechanism in the post-transcriptional regulation of gene expression, which is frequently altered during tumorigenesis. Previously, we have described marked changes in alternative splicing of the CD44 gene in ovarian and breast cancer. In the latter one we described also a specific induction of splicing factors during tumor development. Now we have focussed our studies on the expression profiles of splicing factors, including classical SR proteins, Tra2 and YB-1 in physiological and malignant ovarian tissues by RT-PCR and Western blot analysis. We detected changed expression pattern with higher levels of phosphorylated 30 kDa SR proteins as well as relatively high concentrations of hyperphosphorylated Tra2 protein isoforms in ovarian cancer. RT-PCR analysis revealed a marked induction of SC35 and ASF/SF2 as well as mRNA levels in malignant ovarian tissue. These results suggest gene-specific alterations of expression rather than a general induction of the splicing machinery. Together with previously performed functional studies of CD44 splicing these findings implicate that altered expression profiles of SR proteins, Tra2beta and YB-1 might be responsible for the known changes of alternative CD44 splicing in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15069551

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  39 in total

1.  Alternative splicing as a therapeutic target for human diseases.

Authors:  Kenneth J Dery; Veronica Gusti; Shikha Gaur; John E Shively; Yun Yen; Rajesh K Gaur
Journal:  Methods Mol Biol       Date:  2009

2.  The emerging role of splicing factors in cancer.

Authors:  Ana Rita Grosso; Sandra Martins; Maria Carmo-Fonseca
Journal:  EMBO Rep       Date:  2008-10-10       Impact factor: 8.807

Review 3.  The role of RNA alternative splicing in regulating cancer metabolism.

Authors:  Itamar Kozlovski; Zahava Siegfried; Adi Amar-Schwartz; Rotem Karni
Journal:  Hum Genet       Date:  2017-04-20       Impact factor: 4.132

4.  Transformer 2β and miR-204 regulate apoptosis through competitive binding to 3' UTR of BCL2 mRNA.

Authors:  Y Kuwano; K Nishida; K Kajita; Y Satake; Y Akaike; K Fujita; S Kano; K Masuda; K Rokutan
Journal:  Cell Death Differ       Date:  2014-10-24       Impact factor: 15.828

5.  Spliceosome protein (SRp) regulation of glucocorticoid receptor isoforms and glucocorticoid response in human trabecular meshwork cells.

Authors:  Ankur Jain; Robert J Wordinger; Thomas Yorio; Abbot F Clark
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-21       Impact factor: 4.799

Review 6.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

Review 7.  Therapeutic potential of manipulating VEGF splice isoforms in oncology.

Authors:  Emma S Rennel; Steven J Harper; David O Bates
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

8.  Splicing factor SRSF3 represses the translation of programmed cell death 4 mRNA by associating with the 5'-UTR region.

Authors:  J Kim; R Y Park; J-K Chen; J Kim; S Jeong; T Ohn
Journal:  Cell Death Differ       Date:  2013-11-29       Impact factor: 15.828

Review 9.  Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors.

Authors:  Meike Körner; Laurence J Miller
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

10.  Caffeine regulates alternative splicing in a subset of cancer-associated genes: a role for SC35.

Authors:  Jia Shi; Zhen Hu; Kirk Pabon; Kathleen W Scotto
Journal:  Mol Cell Biol       Date:  2007-11-19       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.